May. 15 at 2:00 PM
$ENSC As programs move to later-stage development, industry visibility starts mattering more.
That was part of the significance behind Ensysce Biosciences’ participation in the inaugural Pain Therapeutics Summit Europe in Amsterdam, where biotech, pharma, and translational medicine leaders gathered to discuss the future of pain treatment.
During the event, CEO Dr. Lynn Kirkpatrick presented “Chemical Control, Clinical Confidence: Rethinking Opioids,” focused on how TAAP™ and MPAR® were designed to reframe pain management at the molecular level.
As attention around safer pain therapies rows, participation in scientific and strategic forums keeps emerging approaches part of the broader industry conversation.
